Fulcrum Therapeutics Inc
FULC
Get informed when a big investor buys or sells
+ FollowMarket Cap$289.93M
Close$
$3.02
20.4% downside
Current Fair Value
20.4% downsideOvervalued by 20.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $289.93 Million |
|---|---|
| Enterprise Value | $246.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 3 |
| Outstanding Shares | 76,264,000 |
Return
| Return on Equity | -27.36% |
|---|---|
| Return on Assets | -26.24% |
| Return on Invested Capital | -29.87% |
Valuation & Multiples
| P/E Ratio | -3.14 |
|---|---|
| PEG | -6.11 |
| Price to Sales | - |
| Price to Book Ratio | 0.95 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.63 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.5941▲ 234.50% |
|---|---|
| Total Calls | 155,200▼ 72.82% |
| Total Puts | 402,600▲ 183.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.80%▲ 10.71% |
|---|---|
| Total Invested | $292.89M▼ 46.76% |
| Investors Holding | 163▼ 12.00% |
ESG Score
No data
About Fulcrum Therapeutics Inc
73 employeesFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies dru...